Human Genome Sciences Submits Biologics License Application To FDA For ZALBIN™
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
People who read this also read
- Of Pfizer, a New Treatment for a Rare Disease and Carrot Cells
Pfizer’s deal today with Israeli biotech Protalix BioTherapeutics to license most of the rights for a promising therapy for a rare disease caught our eye for a number of reasons: The deal gives ... - Progression of Liver Disease
There are many different types of liver disease. But no matter what type you have, the damage to your liver is likely to progress in a similar way. Whether your liver is infected with a virus, injure... - Human Genome Sciences Announces Submission Of Marketing Authorization Application To EMEA For JOULFERON(R) (ZALBIN™)
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (... - Human Genome Sciences Shows Public Offerings Work, Too
With big pharma eager to throw hundreds of millions of dollars at companies with promising experimental drugs, it’s easy to forget that there’s another route for up-and-coming drug makers:... - New Drug Application Submitted To FDA For Tapentadol Extended Release Tablets For Management Of Chronic Pain
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol exten... - Inovio Partner Announces Completion Of Phase I DNA Vaccine Study
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study o... - NVHR: New Data Finding Fewer Than 1 In 5 Hepatitis C Patients Receiving Antiviral Therapy Is ‘Wake-Up Call’ For Washington
New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received anti-viral therapy in recent years should be a wake-up ... - SpinalMotion Submits Lumbar Disc PMA
SpinalMotion, developer of the investigational Kineflex® lumbar and Kineflex/C® cervical disc implants for treating patients with degenerative disc disease (DDD), reported that it has submitted the Pr... - Tripep: The ChronVac-C(R) Study Has Been Successfully Completed With Good Safety And Favorable Clinical Data
All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep's therapeutic vaccine ChronVac-C® have now been collected. The treatment was found to be safe, immunogenic and ... - Student’s Award For Study Into Cancer Drug Target
A PhD student at The Institute of Cancer Research (ICR) has won an Europe-wide competition for her investigation into a promising anti-cancer drug target. Nicole Simonavicius was awarded first pr...


